New Data Shows Physicians Changed Extended Endocrine Therapy Recommendations for Over 40% of Patients Following Breast Cancer Index Testing
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. and its subsidiary, Biotheranostics, Inc., today announced newly published data in JAMA Network Open showing that Breast Cancer Index® (BCI®) test results led physicians to change their extended endocrine therapy recommendations for 42% of patients. In two-thirds of those cases, physicians changed their recommendation against extending treatment.1 The findings come from a large-scale BCI Registry Study conducted across multiple institutions at